Christopher Hourigan
| Christopher Hourigan | |
|---|---|
| Born | |
| 🎓 Alma mater | Oxford University |
| 💼 Occupation | |
| Known for | Acute Myeloid Leukemia and Measurable Residual Disease |
| 🏅 Awards | Alpha Omega Alpha, Johns Hopkins Chapter Honorary Fellow, Royal College of Physicians, NHLBI Directors Award NHLBI Orloff Award NIH Bench to Bedside Award NIH Directors Challenge Innovation Award American College of Physicians Early Career Physician Award American Society for Clinical Investigation Young Physician-Scientist Award Presidential Early Career Award for Scientists and Engineers (2019) |
| 🌐 Website | https://www.nhlbi.nih.gov/science/myeloid-malignancies |
Christopher Hourigan, DM, DPhil is a physician-scientist at the National Heart, Lung, and Blood Institute of the National Institutes of Health in Bethesda, Maryland. He is the Chief of the Laboratory of Myeloid Malignancies".[1]
Dr. Hourigan has published over 90 scientific papers [2] focusing on measurable residual disease (MRD; previously termed minimal residual disease) and the genomic landscape of acute myeloid leukemia.[3][4][5][6][7]
Education
Dr. Hourigan graduated from Oxford University Medical School and received his DPhil for work with Sir John Bell (physician) at the Weatherall Institute of Molecular Medicine at Oxford University. He completed postdoctoral clinical training at Guy's and St Thomas' Hospital in London, Johns Hopkins Bayview Medical Center, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore[1]. He is ABIM board certified in Internal Medicine, Hematology, and Medical Oncology.
Honors and awards
In 2019, Dr. Hourigan received a Presidential Early Career Award for Scientists and Engineers, the highest U.S. government honor for scientists and engineers beginning independent research careers for his research on Measurable Residual Disease in Acute Myeloid Leukemia [8]
The work of his laboratory showing that treatment intensification could improve survival for some patients with Acute Myeloid Leukemia Measurable Residual Disease was selected for plenary presentation as best late-breaking abstract at the Presidential Symposium of the 24th European Hematology Association (EHA) Congress in Amsterdam[9][10][11][12][13], published in the Journal of Clinical Oncology as a rapid communication on the basis of "immediate practice changing potential" [14][15][16][17], awarded the National Heart, Lung, and Blood Institute Orloff Award, and honored as one of the top NIH accomplishments of 2020.
Notable publications [7]
- Hourigan, C. S., Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., ... & Horwitz, M. E. (2020). Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. Journal of Clinical Oncology, 38(12), 1273-1283.[18] (Cited 138 times)
- Horibata, S., Gui, G., Lack, J., DeStefano, C. B., Gottesman, M. M., & Hourigan, C. S. (2019). Heterogeneity in refractory acute myeloid leukemia. Proceedings of the National Academy of Sciences, 116(21), 10494-10503.[19] (Cited 21 times)
- Dillon, L. W., Ghannam, J., Nosiri, C., Gui, G., Goswami, M., Calvo, K. R., ... & Hourigan, C. S. (2021). Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from non-malignant clonal hematopoiesis. Cancer discovery, 2(4), 319. [20] (Cited 4 times)
- Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017). Measurable residual disease testing in acute myeloid leukaemia. Leukemia, 31(7), 1482-1490. [6] (Cited 176 times)
- Hourigan, C. S., & Karp, J. E. (2013). Minimal residual disease in acute myeloid leukaemia. Nature reviews Clinical oncology, 10(8), 460-471.[5] (Cited 189 times)
References
- ↑ 1.0 1.1 "Principal Investigators". NIH Intramural Research Program. Archived from the original on 2021-11-27. Retrieved 2021-11-03.
- ↑ Search Results for author Hourigan CS on PubMed.
- ↑ Schuurhuis, Gerrit J.; Heuser, Michael; Freeman, Sylvie; Béné, Marie-Christine; Buccisano, Francesco; Cloos, Jacqueline; Grimwade, David; Haferlach, Torsten; Hills, Robert K.; Hourigan, Christopher S.; Jorgensen, Jeffrey L. (2018-03-22). "Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party". Blood. 131 (12): 1275–1291. doi:10.1182/blood-2017-09-801498. ISSN 0006-4971. PMC 5865231. PMID 29330221.
- ↑ Tyner, Jeffrey W.; Tognon, Cristina E.; Bottomly, Daniel; Wilmot, Beth; Kurtz, Stephen E.; Savage, Samantha L.; Long, Nicola; Schultz, Anna Reister; Traer, Elie; Abel, Melissa; Agarwal, Anupriya (17 October 2018). "Functional genomic landscape of acute myeloid leukaemia". Nature. 562 (7728): 526–531. Bibcode:2018Natur.562..526T. doi:10.1038/s41586-018-0623-z. ISSN 1476-4687. PMC 6280667. PMID 30333627.
- ↑ 5.0 5.1 Hourigan, Christopher S.; Karp, Judith E. (2013). "Minimal residual disease in acute myeloid leukaemia". Nature Reviews Clinical Oncology. 10 (8): 460–471. doi:10.1038/nrclinonc.2013.100. ISSN 1759-4782. PMC 4163748. PMID 23799371.
- ↑ 6.0 6.1 Hourigan, C. S.; Gale, R. P.; Gormley, N. J.; Ossenkoppele, G. J.; Walter, R. B. (2017). "Measurable residual disease testing in acute myeloid leukaemia". Leukemia. 31 (7): 1482–1490. doi:10.1038/leu.2017.113. ISSN 1476-5551. PMID 28386105. Unknown parameter
|s2cid=ignored (help) - ↑ 7.0 7.1 "Christopher S. Hourigan". scholar.google.com. Retrieved 2021-11-23.
- ↑ "President Donald J. Trump Announces Recipients of the Presidential Early Career Award for Scientists and Engineers – The White House". trumpwhitehouse.archives.gov. Retrieved 2021-11-03.
- ↑ Hourigan, C. "IMPACT OF CONDITIONING INTENSITY OF ALLOGENEIC TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH GENOMIC EVIDENCE OF RESIDUAL DISEASE". EHA Library. European Hematology Association. Retrieved 26 November 2021.
- ↑ Osterweil, Neil (2019-06-25). "MDedge Hematology News". AML variants before transplant signal need for aggressive therapy.
- ↑ Lovely, Brittany (2019-08-15). "OncLive". AML Findings Suggest a Broader Role for Genomic Testing (Volume 20, Issue 16).
- ↑ Melville, Nancy (2019-06-25). "Medscape". Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk.
- ↑ "ecancer". EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?. 2019-06-14.
- ↑ Hourigan, Christopher S.; Dillon, Laura W.; Gui, Gege; Logan, Brent R.; Fei, Mingwei; Ghannam, Jack; Li, Yuesheng; Licon, Abel; Alyea, Edwin P.; Bashey, Asad; Deeg, H. Joachim (2020-04-20). "Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease". Journal of Clinical Oncology. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. ISSN 0732-183X. PMC 7164487 Check
|pmc=value (help). PMID 31860405. - ↑ Stenger, Matthew (2020-01-17). "The ASCO Post". Conditioning Intensity for Allogeneic Transplantation in Patients With AML. Retrieved 27 November 2021.
- ↑ Kuznar, Wayne (2020-02-26). "MEDPAGE TODAY". Christopher Hourigan, DM, DPhil, on Mutation-based MRD and Conditioning for AML.
- ↑ Llobet-Canela, Marta (2020-08-26). "AML Hub". Patients with pretransplant MRD may benefit from conditioning intensification.
- ↑ Hourigan, Christopher S.; Dillon, Laura W.; Gui, Gege; Logan, Brent R.; Fei, Mingwei; Ghannam, Jack; Li, Yuesheng; Licon, Abel; Alyea, Edwin P.; Bashey, Asad; Deeg, H. Joachim (2020-04-20). "Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease". Journal of Clinical Oncology. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. ISSN 0732-183X. PMC 7164487 Check
|pmc=value (help). PMID 31860405. - ↑ Horibata, Sachi; Gui, Gege; Lack, Justin; DeStefano, Christin B.; Gottesman, Michael M.; Hourigan, Christopher S. (2019-05-21). "Heterogeneity in refractory acute myeloid leukemia". Proceedings of the National Academy of Sciences. 116 (21): 10494–10503. doi:10.1073/pnas.1902375116. ISSN 0027-8424. PMC 6535032 Check
|pmc=value (help). PMID 31064876. - ↑ Dillon, Laura W.; Ghannam, Jack; Nosiri, Chidera; Gui, Gege; Goswami, Meghali; Calvo, Katherine R.; Lindblad, Katherine E.; Oetjen, Karolyn A.; Wilkerson, Matthew D.; Soltis, Anthony R.; Sukumar, Gauthaman (2021-05-25). "Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis". Blood Cancer Discovery. 2 (4): 319–325. doi:10.1158/2643-3230.BCD-21-0046. ISSN 2643-3230. PMC 8265308 Check
|pmc=value (help). PMID 34258102 Check|pmid=value (help).
External links
This article "Christopher Hourigan" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Christopher Hourigan. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
